Six new medicines leap towards EU approval
The recommendations include new treatments for cancer and intraocular pressure and prevention of uncomplicated flu.
Read More
Tag: Tivicay
US approves first dispersible tablet formulation of Tivicay
The formulation and an expanded indication for Tivicay tablets are currently under review in Europe
Read More
ViiV’s two-drug HIV regimen hits PhIII targets
ViiV Healthcare’s two-drug HIV regimen of Tivicay and Epivir has hit targets in late-stage trials, showing non-inferiority to a three-drug regimen and thus the potential to offer patients an alternative treatment strategy.
Read More
ViiV kicks off PhIII trial of two-drug HIV regimen
ViiV Healthcare, an HIV specialist firm majority owned by GlaxoSmithKline, has announced the launch of a late-stage study investigating the effectiveness of a two-drug regimen programme in patients with HIV.
Read More
GSK happy with 3 percent rise in 2017 sales
GlaxoSmithKline has reported a sales hike of 3 percent at constant exchange rates (CER*) for 2017, after growth was recorded across all of its three global businesses.
Read More
Gilead’s HIV drug ‘non-inferior’ to ViiV’s Tivicay
Gilead has unveiled data from a batch of late-stage trials showing that its investigational HIV therapy bictegravir was non-inferior to ViiV Healthcare’s flagship drug dolutegravir in suppressing levels of the virus.
Read More
Mixed first quarter fortunes for GSK, AZ
UK-based drug giants GlaxoSmithKline and AstraZeneca have reported a mixed bag of results for the first quarter of the year.
Read More
ViiV kicks off Ph III trials of two-drug HIV regimen
ViiV Healthcare has kicked off a Phase III programme that it hopes will lead to regulatory filings for a two-drug regimen of Tivicay and Epivir as a treatment for HIV in adults who have not received prior antiretroviral therapy.
Read More
- Cure Parkinson’s convenes expert panel to assess £2 million combination therapy funding call
- Kygevvi approved in Europe as first treatment for TK2d
- Tozorakimab shows significant benefit in two major COPD trials
- Daratumumab becomes first oncology injectable approved for patient administration
- Laigo Bio completes final close of €17m seed financing round
